← All trials
NCT03446534
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 7, 2018
- Primary completion
- May 31, 2020
- Completion date
- Dec 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 884
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OsloLead sponsor
- University of OsloReponsible party - principal investigator
- University of OsloOverall official - principal investigator
- Norwegian University of Science and TechnologyCollaborator
- University of StavangerCollaborator
- University Hospital of North NorwayCollaborator
- Oslo Metropolitan UniversityCollaborator
- University of BergenCollaborator
- Helse Møre og Romsdal HFCollaborator
- Nordland HospitalCollaborator
- Government of NorwayCollaborator
- South-Eastern Norway Regional Health AuthorityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.